Theratechnologies Shares New Data on HIV Treatment and Cardiovascular Risk at CROI 2025
$THTX
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on innovative therapies, recently presented new findings at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. The company shared results from two key studies that provide updated insights into the treatment of HIV and the assessment of cardiovascular risk in people living with the virus.
One study presented data from the ongoing PROMISE-US trial, which is evaluating the use of ibalizumab in patients with multidrug-resistant HIV. Despite participants on ibalizumab-based regimens having more advanced disease at the start, they achieved similar rates of viral suppression compared to those on other regimens. Dr. Smitha Gudipati of Henry Ford Hospital emphasized the importance of maintaining fully suppressive therapy for this group, while Dr. Christian Marsolais, Chief Medical Officer at Theratechnologies, highlighted the trial’s real-world relevance in capturing long-term outcomes.
In a separate session, Theratechnologies discussed findings from the VAMOS (Visceral Adiposity Measurement and Observation Study), which examined cardiovascular risk among people with HIV. The study concluded that body mass index (BMI) alone is not a reliable indicator of cardiovascular health, especially for identifying excess visceral abdominal fat (EVAF), a key risk factor in this population. Dr. Karam Mounzer of Philadelphia FIGHT Community Health Centers recommended using additional screening methods, such as waist circumference, for more accurate risk assessment.
The VAMOS data showed that individuals with normal or slightly elevated BMI levels could still have high EVAF, indicating elevated cardiovascular risk that traditional methods might miss. These findings may help guide more effective screening and preventative care strategies for people with HIV. The company continues its work to advance understanding and improve patient outcomes through research and clinical innovation.
DISCLAIMER: THIS CONTENT IS FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE INTERPRETED AS INVESTMENT ADVICE. INVESTING INVOLVES RISK, INCLUDING THE POTENTIAL LOSS OF PRINCIPAL. READERS ARE ENCOURAGED TO CONDUCT THEIR OWN RESEARCH AND CONSULT WITH A QUALIFIED FINANCIAL ADVISOR BEFORE MAKING ANY INVESTMENT DECISIONS.